Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01244685 · ClinicalTrials.gov registry record · NA
Trial With Deltex Cardio in Elective Bowel Resection Patients
A NA study of 1 Fluid Management, sponsored by Stony Brook University.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT01244685: Completed NA study of 1 Fluid Management, sponsored by Stony Brook University.
NCT01244685 is a NA study of 1 Fluid Management that has completed, run by Stony Brook University. The registered enrollment target is 58 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01244685, a NA study of 1 Fluid Management, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is: * To determine if the intraoperative fluid administration with the Deltex CardioQ esophageal Doppler will reduce the length of stay after elective bowel resection. * The probe can be used to dynamically measure stroke volume and cardiac output. This information will assist us in determining the ideal amount of fluids to be administered. * To determine if the fluid administration established by the esophageal probe will result in a shorter length of stay in elective bowel resection patients. * The investigators plan to enroll 100 patients in this study.
Primary Outcome
Length of hospital stay from day of admission to day of discharge
Conditions Studied
Interventions
- DEVICE Deltex CardioQ Probe
Study Locations (1)
New York
- Stony Broook University Medical Center - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-11 |
| Phase | NA |
What the finished NCT01244685 record still lists
NCT01244685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with 1 Fluid Management appearing as the primary indexed condition, and to 1 intervention - of which Deltex CardioQ Probe is the first listed.
NCT01244685 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01244685 about?
NCT01244685 is a clinical study titled "Trial With Deltex Cardio in Elective Bowel Resection Patients". The purpose of this study is: * To determine if the intraoperative fluid administration with the Deltex CardioQ esophageal Doppler will reduce the length of stay after elective bowel resection. * The probe can be used to dynamically measure stroke volume and cardiac output. This information will as...
What is the current status of trial NCT01244685?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2010-03. Estimated completion is 2011-11.
What conditions does trial NCT01244685 study?
This clinical trial studies the following conditions: 1 Fluid Management.
What interventions are being tested in trial NCT01244685?
The interventions under investigation include: Deltex CardioQ Probe (DEVICE).
Who is sponsoring clinical trial NCT01244685?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01244685 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01244685's enrollment target sits among peer trials
58 1256th of 2000 higher than 740 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia